Click image to enlarge
Category: Outsourced Compounding Services (503B) (Click here to return)
Response to Market Shortages
QuVa Pharma, Inc
Click here to view supplier website

As an emerging leader in 503B compounding outsourcing, QuVa Pharma has responded to market demands with increased capability and capacity. Its cGMP ability to produce sterile-to-sterile and API-to-sterile products increases available, safe options for health care providers during times of chronic shortages. QuVa Pharma now has three FDA-registered 503B sterile compounding facilities (two in Texas
and one in New Jersey), and an anticipated 90,000 square-feet of additional space as of Q4 2018.

Click here to request more information
Entry published in PP&P April 2018